- Targeting cancer stem cells improves treatment effectiveness and prevents metastasis
Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinoma—the most common head and neck cancer and the second-most common skin cancer—according to a new study by cancer researchers at the UCLA School of Dentistry
March 09, 2017 9:00 AMdetail
- Guidelines for treating brain metastases should be overhauled, UCLA study finds
An extensive study by UCLA researchers looking at current practice patterns among doctors treating people with three or more brain metastases—cancer cells that have spread from a primary tumor located in a different part of the body—found significant variation in treatment strategies, bringing to light the need for further research to guide physicians' decision making.
March 01, 2017 9:00 AMdetail
- DNA patterns can unlock how glucose metabolism drives cancer, study finds
Less aggressive cancers are known to have an intact genome—the complete set of genes in a cell—while the genome of more aggressive cancers tends to have a great deal of abnormalities. Now, a new multi-year study of DNA patterns in tumor cells suggests that these aberrant genetic signatures are not random but reflect selective forces in tumor evolution.
February 15, 2017 9:00 AMdetail
- Scientists discover why some cancers may not respond to immunotherapy
UCLA scientists have discovered that people with cancers containing genetic mutations JAK1 or JAK2 will have little or no benefit from the immunotherapy drug, pembrolizumab.
February 06, 2017 3:00 AMdetail
- UCLA cancer research pioneer honored for advancing the understanding of treatment-resistant melanoma
The AACR will honor Dr. Roger Lo, an accomplished physician-scientist widely recognized his work in understanding treatment-resistant melanoma, with its first annual Waun Ki Hong Award for Outstanding Achievement in Cancer Research
January 30, 2017 10:00 AMdetail
- Combination therapy for glioblastoma shows promising results in early-stage research
UCLA researchers have discovered that combining a vaccine developed at UCLA with other experimental therapies and FDA-approved treatments shows promise for reducing the size of advanced brain tumors. The immunotherapy, which is specifically intended to treat brain tumors, is called autologous tumor lysate-pulsed dendritic cell vaccination. It uses a portion of the patient's own brain tumor and is currently being tested in humans.
January 23, 2017 6:00 AMdetail
- The unexpected intersection between art and science
It’s a common misconception that art and science are vastly different; that they never overlap. But creativity is as essential to the scientific process as it is to the artistic method. Artists and scientists share a curiosity for the unknown, an appreciation for the beauty of the worlds they explore and an interest in creating something new.
January 19, 2017 10:30 AMdetail
- With $3.2 million grant from NIH, UCLA researcher to optimize selection of lung cancer patients for immunotherapy
Dr. Edward Garon, UCLA Jonsson Comprehensive Cancer Center member and associate professor of hematology and oncology at the David Geffen School of Medicine, has received a five-year, $3.2 million grant from the National Institutes of Health to advance the understanding of which people with non-small cell lung cancer respond to immunotherapy.
January 17, 2017 9:30 AMdetail